Doliculide (325) inhibits proliferation and impairs the migratory potential of human MCF-7 and MDA-MB-231 breast cancer cells, while modifying senescence-related genes at non-toxic concentrations in p53 wild-type cancer cells by up to 13% [713]. This evidence concerns the gene TP53 and breast carcinoma.